Abstract:Abstract Background and Aims Despite current therapies, more than 43% of patients undergoing dialysis in the USA have hyperphosphatemia, defined as serum phosphate values >5.5 mg/dL and is commonly associated with an increased risk of death. Most currently available phosphate binders are known to cause gastrointestinal (GI) adverse events (AEs) that can negatively impact the patient experience. Common GI AEs include abdominal pain, nausea, and bloating. Phosphate binders are usually formulated as large tablets, and some must be chewed before ingestion. Commonly a high number of pills are needed per day to achieve goal serum phosphate levels. Oxylanthanum carbonate (OLC) is a new lanthanum-based nanotechnology product in development with a high in vitro binding capacity as compared to other phosphate binders. OLC is formulated as a small pill that is swallowed whole instead of being chewed before swallowing as is the case for lanthanum carbonate. The safety of OLC has been studied in >100 healthy subjects. The most common treatment-related AE (>5%) in an OLC bioequivalence (BE) study was nausea. This study aims to evaluate the tolerability of clinically effective (serum phosphate ≤5.5 mg/dL) doses of OLC in patients on hemodialysis. Method This open-label, single-arm, multicenter, multidose study will enroll up to 90 patients on hemodialysis who require phosphate binder therapy and have mean historical serum phosphate levels between ≥4.0 and ≤7.0 mg/dL for ≥8 weeks. The primary endpoint of the study is tolerability as assessed by the incidence of discontinuations due to treatment-related AEs. Additionally, the incidence of AEs related to OLC will be collected. Participants will undergo up to 3 weeks of phosphate binder washout until their serum phosphate levels reach >5.5 and ≤10.0 mg/dL (Fig. 1). During the 6-week Titration Period, all patients will receive 1500 mg/day OLC (500 mg TID with meals/snacks) for the initial 2 weeks, with subsequent titration every 2 weeks until achieving a target serum phosphate level (≤5.5 mg/dL) or to a maximum OLC dose of 3000 mg/day. After titration, patients will enter a 4-week Maintenance Period at the effective OLC dose. Results We intend to present results elucidating tolerability of clinically effective doses of OLC in patients on dialysis. Conclusion The tolerability of OLC at doses effective in achieving a serum phosphate ≤5.5 mg/dL in patients on hemodialysis will be evaluated in this study.

Additional Reduction in Serum Phosphorus Levels by Pulverized Lanthanum Carbonate Chewable in Hemodialysis Patients

Is Granular Formulation of Lanthanum Carbonate More Effective than Chewable Tablets?

Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients

Phosphate‐binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients

Effects of Change in the Formulation of Lanthanum Carbonate on Laboratory Parameters

Lanthanum Carbonate for the Treatment of Hyperphosphatemia in Ckd 5d: Multicenter, Double Blind, Randomized, Controlled Trial in Mainland China

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

Questionnaire Survey and Serum Phosphorus Levels in Maintenance Hemodialysis Patients Switching Lanthanum Carbonate Formulation From Chewable Tablets to Granules

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Effects of lanthanum carbonate on serum phosphorus in maintenance hemodialysis patients receiving calcitriol pulse therapy due to secondary hyperparathyroidism

Lanthanum Carbonate for Treating End Stage Renal Disease Patients with Hyperphosphatemia：a Rapid Assessment

Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects

Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients

An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis

Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.

The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease

Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate

Lanthanum: a safe phosphate binder

#346 Oxylanthanum carbonate for hyperphosphatemia in ESKD: tolerability trial in progress

Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study